Cargando…

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

OBJECTIVE: Non-alcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, inflammation and fibrosis. There are currently no targeted therapies for NASH. We developed a liver-specific LXR inverse agonist, SR9238, which effectively reduces hepatic lipogenesis in models of obesity and hepa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griffett, Kristine, Welch, Ryan D., Flaveny, Colin A., Kolar, Grant R., Neuschwander-Tetri, Brent A., Burris, Thomas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354919/ https://www.ncbi.nlm.nih.gov/pubmed/25830098 http://dx.doi.org/10.1016/j.molmet.2015.01.009

Ejemplares similares

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis
por: Sengupta, Monideepa, et al.
Publicado: (2021)

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
por: Huang, Peng, et al.
Publicado: (2018)

An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis
por: Ulmasov, Barbara, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle
por: Welch, Ryan D., et al.
Publicado: (2017)

Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
por: Wu, Guangzhen, et al.
Publicado: (2019)

LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer
por: Carpenter, Katherine J., et al.
Publicado: (2019)

TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis
por: Hsieh, Joanne, et al.
Publicado: (2016)

coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment
por: Clearfield, Elizabeth, et al.
Publicado: (2021)

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2018)

Reduction of fibrosis and immune suppressive cells in ErbB2-dependent tumorigenesis by an LXR agonist
por: Sheng, Gao, et al.
Publicado: (2021)

Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
por: Sharpe, Martin C., et al.
Publicado: (2023)

Association between trauma and socioeconomic deprivation: a registry-based, Scotland-wide retrospective cohort study of 9,238 patients
por: Corfield, Alasdair R., et al.
Publicado: (2016)

Two Faces of Pioglitazone: Sorting Out the Roles of its PPARγ Binding Versus Mitochondrial Pyruvate Carrier Inhibition Is Not So Simple
por: Yuan, Liyun, et al.
Publicado: (2021)

Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice
por: Welch, Ryan D., et al.
Publicado: (2020)

REV-ERB activation as a novel pharmacological approach for treating inflammatory pain
por: Makhija, Sangeet, et al.
Publicado: (2023)

LXR-Mediated Inhibition of CD4(+) T Helper Cells
por: Solt, Laura A., et al.
Publicado: (2012)

REV-ERB agonism improves liver pathology in a mouse model of NASH
por: Griffett, Kristine, et al.
Publicado: (2020)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

A Rare Cause of Upper Gastrointestinal Bleeding: Sarcina ventriculi
por: Worrall, Emily B., et al.
Publicado: (2022)

Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells
por: Rough, James J, et al.
Publicado: (2010)

Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)

The liver X receptor agonist LXR 623 restricts flavivirus replication
por: Mlera, Luwanika, et al.
Publicado: (2021)

Flindissone, a Limonoid Isolated from Trichilia prieuriana, Is an LXR Agonist
por: Resetar, Mirta, et al.
Publicado: (2023)

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis
por: Sanyal, Arun, et al.
Publicado: (2023)

The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance
por: Gill, Ryan M., et al.
Publicado: (2023)

Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis
por: Mukherjee, Sandip, et al.
Publicado: (2021)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells
por: DiBlasio-Smith, Elizabeth A, et al.
Publicado: (2008)

Approved LXR agonists exert unspecific effects on pancreatic β-cell function
por: Maczewsky, Jonas, et al.
Publicado: (2020)

Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis
por: Dragoljevic, Dragana, et al.
Publicado: (2023)

Thrombomodulin activation driven by LXR agonist attenuates renal injury in diabetic nephropathy
por: Wang, Wei, et al.
Publicado: (2023)

Interactions between Bile Acids and Nuclear Receptors and Their Effects on Lipid Metabolism and Liver Diseases
por: Wang, David Q.-H., et al.
Publicado: (2012)

Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
por: Chen, Yu-jun, et al.
Publicado: (2021)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Inappropriate Testing for Acute Viral Hepatitis Is Common—Impact of an Intervention Using the Electronic Health Record in a Tertiary Teaching Hospital in the United States
por: Hammami, Muhammad Bader, et al.
Publicado: (2020)

Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice
por: Ulmasov, Barbara, et al.
Publicado: (2016)

LXR agonist improves peripheral neuropathy and modifies PNS immune cells in aged mice
por: Gavini, Chaitanya K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qe00ju98thb9gvshmbqh54gek0